CRL shares have surged 75.8% in a year as RMS trends improve, AI-enabled testing expands and cash flow supports buybacks and investment.

Charles River Laboratories International and Autolomous launched Apollo Orchestrate, a new Apollo platform capability that digitizes GMP quality control workflows across North America and Europe using the autoloMATE Laboratory Execution System. The shift from paper records to a connected digital workflow is expected to result in fewer manual steps, tighter data traceability, and a more scalable QC operating model across Charles River’s Biologics Testing Solutions network. This development...

Charles River Laboratories International and Autolomous launched Apollo Orchestrate, a new Apollo platform capability that digitizes GMP quality control workflows across North America and Europe using the autoloMATE Laboratory Execution System. The shift from paper records to a connected digital workflow is expected to result in fewer manual steps, tighter data traceability, and a more scalable QC operating model across Charles River’s Biologics Testing Solutions network. This development...

Charles River Laboratories stock fell to USD 304.96 on October 6, 2026, after a sharp session declin

CRL targets 5.00 percent to 7.00 percent organic growth through 2030. Charles River Laboratories sto

Get the latest Charles River Laboratories International, Inc. (CRL) stock news and headlines to help you in your trading and investing decisions.

Charles River (NYSE:CRL) is in focus as preclinical services demand and biotech funding shape the outlook. Explore the key themes and milestones to watch next.